Export 90 results:
Author [ Title(Desc)] Type Year
Filters: Author is Cruz, F.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Cruz, F., Herschorn, S., Aliotta, P., Brin, M., et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. European Urology, 60(4), 742 - 750.
Martins-Silva, C., & Cruz, F. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European Urology Focus, 2(3), 329 - 331.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Tomada, N., Tomada, I., Botelho, F., Pacheco-Figueiredo, L., et al. (2013). Endothelial function in patients with metabolic syndrome and erectile dysfunction: A question of Angiopoietin imbalance?. Andrology, 1(4), 541 - 548.
Cruz, C. D., & Cruz, F. (2007). The ERK 1 and 2 pathway in the nervous system: From basic aspects to possible clinical applications in pain and visceral dysfunction. Current Neuropharmacology, 5(4), 244 - 252.
Antunes-Lopes, T., C. da Silva, M., & Cruz, F. (2016). Evaluation of the Donor After Brain Death and Technique for Organ Procurement. European Urology, Supplements, 15(9), 390 - 396.
Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-month follow-up. European Urology, 59(6), 940 - 944.
Gorgal, T., Charrua, A., Silva, J. F., Avelino, A., et al. (2012). Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection. BMC Urology, 12.
Oliveira, R., Coelho, A., Charrua, A., Avelino, A., & Cruz, F. (2017). Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice. Neurourology and Urodynamics, 36(1), 86 - 90.
F
Dinis, S., De Oliveira, J. T., Pinto, R., Cruz, F., et al. (2015). From bladder to systemic syndrome: Concept and treatment evolution of interstitial cystitis. International Journal of Women's Health, 7, 735 - 744.
Charrua, A., Reguenga, C., Cordeiro, J. M., Correiade-Sá, P., et al. (2009). Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. Journal of Urology, 182(6), 2944 - 2950.
G
Charrua, A., Cruz, C. D., Narayanan, S., Gharat, L., et al. (2009). GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 181(1), 379 - 386.
H
Da Silva, C. M., & Cruz, F. (2009). Has botulinum toxin therapy come of age: What do we know, what do we need to know, and should we use it?. Current Opinion in Urology, 19(4), 347 - 352.
I
Coelho, A., Oliveira, R., Cruz, F., & Cruz, C. D. (2016). Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. Experimental Neurology, 285, 159 - 166.
Cruz, C. D., Avelino, A., McMahon, S. B., & Cruz, F. (2005). Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. European Journal of Neuroscience, 21(3), 773 - 781.
Cruz, C. D., Neto, F. L., Castro-Lopes, J., McMahon, S. B., & Cruz, F. (2005). Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain, 116(3), 411 - 419.
Guimarães, M., Oliveira, R., Pinto, R., Soares, A., et al. (2009). Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. BJU International, 103(4), 500 - 504.
Silva, J., Pinto, R., Carvalho, T., Botelho, F., et al. (2011). Intraprostatic botulinum toxin type A administration: Evaluation of the effects on sexual function. BJU International, 107(12), 1950 - 1954.
Silva, J., Silva, C., Saraiva, L., Silva, A., et al. (2008). Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption. European Urology, 53(1), 153 - 159.
Silva, J., Pinto, R., Carvalho, T., Botelho, F., et al. (2009). Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: Duration of the effect of a single treatment. BMC Urology, 9(1).
Cruz, C. D., Charrua, A., Vieira, E., Valente, J., et al. (2008). Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Experimental Neurology, 214(2), 301 - 308.
Charrua, A., & Cruz, F. (2015). Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders. In TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use (pp. 119 - 127).
Dinis, P., Charrua, A., Avelino, A., & Cruz, F. (2004). Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU International, 94(1), 153 - 157.
M
Cruz, F. (2004). Mechanisms involved in new therapies for overactive bladder. Urology, 63(3 SUPPL. 1), 65 - 73.
Silva, J., Pinto, R., Carvallho, T., Coelho, A., et al. (2009). Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. European Urology, 56(1), 134 - 141.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@i3s.up.pt | © copyright 2010 ibmc